David Zaccardelli - Nov 11, 2024 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
President and CEO, Director
Signature
/s/ Andrew Fisher, Attorney-in-fact for David Zaccardelli
Stock symbol
VRNA
Transactions as of
Nov 11, 2024
Transactions value $
-$12,000
Form type
4
Date filed
11/13/2024, 04:58 PM
Previous filing
Nov 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Sale -$12K -2.4K -0.02% $5.00 15.2M Nov 11, 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024.
F3 Consists of (i) 3,000,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 375,000 ADSs); and (ii) 12,202,352 Ordinary Shares underlying 1,525,294 ADSs.